Which are the major products in company's basket?
We have a product basket of 75+ drugs, out of which 13 are our novel research products in the segment of anti cancer, Anti infective, Cardiovascular and Neurology related products. We have gained global accolades for our remedy redefining blockbuster brands, of which 11 are commercialized across the globe. Venus has a broad range of products catering to critical care segment in parenterals like cephalosporins, carbapenems and oncology drugs in lyophilized form, infusions and small volume parenterals.

Company has bagged more than 80 patents across the world for its research products such as Potentox, Vancoplus, CSE 1034, Tobracef, ACHNIL and so on. The company currently has products in segments of anti-infective, oncology, cardiovascular and neurology Orthopedics, Pediatrics, Gynecology, Critical Care Segment. Deeply rooted in these specialty segments VRL is a leader with its competent products and innovative solutions.

We are in the process of coming up with some revolutionary products in the near future. We presently have a pipeline of around 25 products, which are at different phases of development. Furthermore, a novel antibiotic adjuvant entity with the brand name ''Elores'' would be launched by the company early next year, which has a proven efficacy against the multiple antimicrobial resistance mechanisms in gram negative bacteria. It has already received US patent grant from the US Patent Office.

What is the business model of the company and how is performance revenue wise?
Our business model is focussed on our own research based products in the fields of oncology, anti-infective, cardiovascular and neurology. We have already made good in-roads into Antimicrobial resistance that we plans to encash in near future. We would like to enhance our penetration in global markets through strategic alliances on the strengths of product ownership and protection. The company had an annual turnover of Rs 405 crore in the financial year 2011-12 and it is expecting this growth trajectory to keep going higher.

How do you look at future of the company? Are there any exceptional plans in pipeline?
Being a research driven company, we are very optimistic about the future. With the number of patent grants we have been receiving from across the well established and emerging markets of the globe for our novel research products, we have engaged some renowned consultants to forge strategic tie up deals for us. This would be an important step for us to utilise our achievements in the research field and make the most of it. Thus, we see a bright future for us to thrive and fulfill what we aim for at Venus.

Yes, we do have plans in pipeline, which we maintain all the time to provide effective solution to life threatening diseases and is currently working on a robust pipeline of 25 products at various stages of development, including the 12 novel products that have already been commercialized.